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sensus, the assessment of a third investigator was requested. Results: Bariatric 
surgery showed to be effective and safe in reducing glycated hemoglobin levels, 
fasting blood glucose levels as well as the augmenting the chances of remission 
of type II diabetes in obese patients. ConClusions: However, the variability in 
the magnitude of the results indicated the need for new data from the 18 ongoing 
clinical trials. In other words, the technology “bariatric surgery” is efficacious as a 
whole, but there is a high variability in the treatment effect, depending of surgical 
technique.
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objeCtives: During the progressive course of type 2 diabetes mellitus (T2DM) a 
sizeable proportion of patients require insulin therapy to maintain long-term glyce-
mic control. The objective of this study was to realize a snapshot of characteristics 
and glycemic control of patients with T2DM treated by insulin in five European 
countries. Methods: T2DM patients, over 40 years old, treated by insulin (basal 
only therapy [BOT], premix, prandial or a basal-prandial free combination) ± non-
insulin antidiabetic drugs for at least 18 months, were identified in primary care 
electronic medical record databases of France, Italy, UK; Germany and Spain (IMS 
Health Longitudinal Patient Databases) during years 2013-2014. Patients’ charac-
teristics, medical history, treatment regimen, HbA1c values were retrieved and 
analyzed Results: Median age was 71.4 years in Italy (n= 7339), 70 in Germany 
(n= 3079), 67 in UK (n= 16,941), 68.2 in France (n= 3046) and 70.3 in Spain (n= 1710). 
About half of patients had a BMI ≥ 30 and hypertension was present in 69% (UK) to 
88% (Germany). A majority was treated with BOT in France (51%) and Spain (60%), 
basal-prandial in Italy (48%) and in Germany (33%), and premix insulin in UK (41%). 
BOT was the second most commonly prescribed regimen in Germany and Italy. 
Metformin was the most frequently prescribed concomitant oral antidiabetic drug. 
Mean HbA1c was 7.8% in Italy, 7.7% in Germany, 8.4% in UK, 7.9% in France and 8% 
in Spain. Overall, more than three quarter of patients (between 74% in Italy and 
83% in UK) had a HbA1c ≥ 7%, whilst 33% (Germany) to 55.5% (UK) of them had 
a HbA1c ≥ 8%. ConClusions: While regimens and patients characteristics may 
vary among countries, these results show that, despite having been treated with 
insulin for at least 18 months, a sizeable proportion of patients exhibit a suboptimal 
glycemic control.
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objeCtives: With the introduction and delisting of some glucose-lowering medi-
cations, pharmacological treatments in T2D have changed in the recent years and 
details of the current drug use patterns are not known. This descriptive study aims 
to describe characteristics of patients with type 2 diabetes and patterns of use of 
antihyperglycemic agents in France in 2013. Methods: A random sample of ≈ 
600,000 patients registered in the French national health insurances reimburse-
ment database was used. Patients with diabetes were identified through their use of 
glucose-lowering medication and coding of hospital stays and long-standing condi-
tion insurance coverage in the database. Drug utilization pattern of antihyperglyce-
mic agents were estimated considering prescriptions in Q4 2013 and compared to 
data from Q4 2007. Results: Overall 28,708 patients with T2D (estimated database 
prevalence 4.5%, 8.8% in people aged 40 and over) were identified in 2013. Mean age 
was 67.5 (SD 12.9), 54.1% were male. In Q4, 41.2% of T2D pharmacologically treated 
patients received a monotherapy, 25.6% a dual therapy, 13.7% a multi-therapy and 
19.5% an insulin therapy with or without other hypoglycemic agents. Compared to 
2007 data, a slight but significant increasing trend toward combination therapies 
and insulin was observed. The use of metformin increased over time especially in 
monotherapy (66% among monotherapy in 2013 versus 50% in 2007). All thiazolidin-
ediones and some sulfonylureas treatments were replaced by DPP-4 inhibitors and 
to a much lesser extent with GLP-1 analogues. ConClusions: Antihyperglycemic 
prescription patterns in France have changed in recent years in parallel with the 
introduction of different classes of medications to the marketplace but probably 
also in an attempt to improve glycemic control of patients. Knowledge of real life 
pattern of drug utilization remains an important dimension to better understand 
therapeutic needs in T2D management.
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objeCtives: Diabetes in the elderly is a major challenge both in terms of clinical 
management and of public health. Evidence about prescribing patterns in the elderly 
diabetic population is limited. The aim of the present study was to describe trends in 
antidiabetic drug (AD) utilization patterns in the elderly in Southern Italy with a focus 
on drugs for cardiovascular prevention and pharmaceutical costs. Methods: The 
data used for this retrospective cross-sectional study was obtained from pharmacy 
records of Caserta Local Health Authority. Subject > 65 years who received at least 
one dispensing of antidiabetic between January2010-December2014 were selected. 
be more efficacious than other GLP-1 analogues in reducing HbA1c (mean change 
-1.1%/-1.2% for liraglutide 1.2mg/1.8mg; -0.6%/-0.9% exenatide 5mcg/10mcg BID; 
-0.6% lixisenatide 20mcg). Liraglutide was superior or comparable to other GLP-1 
analogues in terms of weight, PPG, SBP, and FPG. ConClusions: Liraglutide offers 
efficacious treatment in terms of HbA1c, FPG, PPG, SBP compare to other GLP-1 
analogues and seems to offer a weight control advantage among patients on mul-
tiple OADs. The likelihood of hypoglycemic events does not appear to differ among 
GLP-1s. Our analysis was limited by the relatively small number of studies available 
and we were not able to adjust for some observed differences in patient charac-
teristics, which may have affected the evaluation. As such, the findings should be 
interpreted with some caution.
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objeCtives: To evaluate relative efficacy and safety of SGLT2i compared to DPP4i 
in patients with type 2 diabetes mellitus (T2DM) in the absence of head-to-head 
evidence. Methods: A systematic search of the literature was conducted in 
MEDLINE, EMBASE, LILACS, the Cochrane Central Register of Controlled Trials, and 
Clinicaltrials.gov to June 2015. Selected studies were randomized controlled trials 
(RCTs) that compare DPP4i plus insulin (DPP4i/INS) or SGLT2i plus insulin (SGLT2i/
INS) with placebo plus insulin (PCB/INS), as a common comparator, in patients 
with T2DM. The primary outcome was the change in HbA1c from baseline to the 
end of the intervention period. The secondary outcomes included the change in 
fasting plasma glucose, the change in body weight, and the event of hypoglyce-
mia. Covariate-adjusted indirect comparison using meta-regression analyses was 
performed. Results: We included 15 eligible RCTS comprising 6,980 patients, of 
which 9 were DPP4i studies and 5 were SGLT2i studies. Covariate-adjusted analy-
ses showed that SGLT2i/INS achieved greater reduction in HbA1c (WMD -0.24%, 
95% CI -0.43 to -0.05%) and fasting plasma glucose (WMD -18.0mg/dL, 95% CI -28.5 
to -7.6 mg/dL) with greater weight reduction (WMD -2.38 kg, 95% CI -3.18 to -1.58 
kg) than DPP4i/INS without increasing the risk of hypoglycemia (RR 1.19, 95% CI 
0.78 to 1.82). ConClusions: The addition of SGLT2i on top of pre-existing insulin 
therapy exhibits a better glycemic control and greater weight reduction than DPP4i 
in patients with inadequately controlled T2DM.
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objeCtives: Sodium-glucose transport protein 2 (SGLT-2) inhibitors demonstrate 
favorable efficacy profiles that include glycemic control and reductions in body 
weight but are associated with adverse events including ketoacidosis, urinary 
tract infections, candida vulvovaginitis, and hypoglycemia. This comparative 
safety and efficacy analysis is designed to compare relevant clinical endpoints 
in the prescribing information labels of available SGLT-2 inhibitors and identify 
the most prevalent and clinically significant outcomes which are crucial in the 
management of patients with type 2 diabetes (T2D). Methods: A multivariate 
analysis was undertaken using clinical endpoints from product information labels 
(n= 3; canaglifozin, dapagliflozin, empagliflozin) of available SGLT-2 inhibitors. 
Compounds with 24- to 26-week, placebo-controlled endpoint data were analyzed. 
Efficacy endpoints included change from baseline in hemoglobin A1c (%) and 
body weight (kg). The safety endpoints included percentage of patients reporting 
adverse events, including urinary tract infections, female genital mycotic infec-
tions, and incidence of hypoglycemic events (%). Results: No compound outper-
formed competitors in all predefined outcome measures after 24- to 26- weeks 
of treatment. Canagliflozin 300 mg + metformin reported the greatest reduction 
in body weight (-4.07 kg) and the greatest reduction in HbA1c (-1.06%). However, 
canagliflozin 300 mg + metformin (4.6%) reported the greatest incidence of hypo-
glycemia events and the greatest incidence of urinary tract infections (11.4%) 
after 26 weeks. ConClusions: Despite the robust efficacy profiles presented in 
this analysis, physicians should consider the potential adverse events associated 
with each SGLT-2 inhibitor before deciding on a treatment regimen. Diabetes treat-
ment regimens are often highly individualized, and healthcare providers must 
weigh the benefits of any treatment with its attendant risks. Of special concern 
among SGLT-2 inhibitors is the recent US FDA warning of increased risk for diabetic 
ketoacidosis associated with these compounds.
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objeCtives: Evaluate the results on the efficacy and safety of bariatric surgery vs. 
medical treatment in remission of type 2 diabetes mellitus (T2DM) and control of 
blood glucose levels in patients with Body Mass Index ≥ 30. Methods: Following 
the methodological guidelines for the development of PTC Ministry of Health, was 
first drafted the guiding question of the study through the PICO, then a search was 
conducted in the main databases (PubMed, Embase, Cochrane, Lilacs and CRD). Each 
study recovered in the databases was selected and evaluated by two independent 
researchers, their inconsistencies resolved by consensus, when there was no con-
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objeCtives: The current study examined the trends in the incidence and prevalence 
of type 2 diabetes mellitus (T2DM) in the Medicare population. Methods: A prospec-
tive population-based study was performed from January 1, 2008 through December 
31, 2013, to determine the prevalence and incidence of patients diagnosed with T2DM 
(International Classification of Disease, 9thRevision, Clinical Modification diagnosis 
codes 250.x0 and 250.x2) from the Medicare population. Patients with continuous 
enrollment in fee-for-service Medicare throughout the calendar year and at least 2 
years prior, were included for study. The age- and gender-adjusted prevalence and 
incidence (overall and specified by age group and gender) of T2DM were calculated 
using direct standardization to the U.S. population aged 65 years or older in 2010, 
using gender-specific age groups. Results: The annual adjusted overall prevalence 
of T2DM increased from 27.92% in 2008 to 32.00% in 2013, whereas the annual overall 
incidence rate decreased from 4.60% in 2008, to 2.79% in 2013. T2DM prevalence and 
incidence rates were higher among men compared to women, every year. Patients 
aged 80-84 had the highest prevalence rate in 2008 (30.40%) and 2011 (36.16%), whereas 
in 2012 (37.46%) and 2013 (38.57%), patients aged 85-89 had the highest prevalence 
rates. From 2008 to 2013, there was a steady growth in the prevalence rates among 
patients older than 75. In 2008, the highest T2DM incidence was observed in the Virgin 
Islands (9,885 per 100,000 person-years). In 2013, the highest incidence of T2DM was 
in New Jersey (6,143 per 100,000 person-years). ConClusions: From 2008 to 2013, 
T2DM prevalence increased and incidence decreased. Men were more likely to be 
diagnosed with T2DM compared to women.
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objeCtives: India as said to be the diabetic capital of the world. This systematic 
review aims to determine the association between socioeconomic status (SES) and 
complications associated with Type 2 Diabetes Mellitus. Methods: Literature 
search was conducted in databases such as PubMed, EMBASE and the Cochrane 
library without any restrictions. References of the included studies were screened 
for additional studies. We included observational studies focussing on association 
between SES and T2DM patients. The quality of the studies was assessed using the 
Newcastle-Ottawa scale. Two authors independently performed the study selection, 
data extraction and the quality assessment process. A third author reviewed the 
output and adjudicated discussions in case of disagreement. Results: A total of 
440 studies were retrieved by the databases search, of which only 4 studies were 
included in the final review. One study reported that T2DM population with SES 
groups were at high risk for developing visual impairment (odds ratio [OR] 2.91; 95% 
confidence interval [CI] 1.24-6.85). Similarly, another study showed high prevalence 
of diabetes peripheral neuropathy in lower SES (48.4%) group compared to upper 
SES group (10.2%). A positive association of cataract was observed in low SES group 
compared to higher SES group (OR 1.67; 95% CI 1.10-2.54; one study). In contrast to 
these findings, one study reported no significant differences between SES groups 
in the occurrence of any form of micro-vascular complications. ConClusions: 
The present review found very limited evidence regarding the association between 
socioeconomic status and diabetes complications. The available evidence suggest 
that diabetic peripheral neuropathy and eye related complications are high in low 
SES population, suggesting the need for educating patients with low SES to prevent 
long term complications in Indian T2DM patients. More observational studies are 
required to be conducted in the future in this context.
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objeCtives: The aim of the study was to explore the association of waist circumfer-
ence with glycaemic control in Malaysian patients with type 2 diabetes. Methods: 
We utilised data of type 2 diabetes patients followed up in Malaysian public sec-
tor primary care clinics contained in the National Diabetes Registry in the year 
2012. The variable of interest was poor glycaemic control, defined as HbA1c≥ 6.5%. 
Multiple logistic regression was used to explore the association between glycae-
mic control and waist circumference, which was adjusted for age, sex, duration of 
diabetes, systolic blood pressure, total cholesterol, use of insulin and other medica-
tions. Results: A total of 98,825 patients with type 2 diabetes were included in the 
study. The mean age of patients was 59.9 years (SD: 10.9) and 38.9% were males. The 
mean duration of diabetes was 6.8 years (SD: 5.0) and 76.2% of patients had HbA1c 
≥ 6.5%. The mean waist circumference was 94.0 cm (SD: 11.8) for male and 90.7 cm 
(SD: 11.8) for female; while 78.3% of the patients had waist circumference above the 
cut-off (≥ 90 cm for men and ≥ 80 cm for women). Larger waist circumference was 
found to be significantly associated with HbA1c≥ 6.5% (adj. OR 1.009; p< 0.001; 95% 
CI: 1.007–1.011) after adjusting for confounding factors. ConClusions: Analysis 
showed that glycaemic control was poorer in patients with higher waist circumfer-
ence than in patients with lower waist circumference.
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Prevalence and incidence rates of AD use were calculated for each calendar year and 
stratified by class therapy and age group. Sub-analyses by cardiovascular co-medi-
cation therapy and pharmaceutical cost analysis were performed. Results: Overall, 
the prevalence rate decreases from 22.0%-17.5% 2010-2014 (p< 0.001). Proportion of 
subjects treated with monotherapy increases over the study period (33,9%-38,6% 2010-
2014; p< 0.001). In particular, increases the proportion of users of metformin (18,2%-
23,7% 2010-2014; p< 0.001), while the proportion of users of sulfonylureas dropped 
(11,0%-7,2% 2010-2014; p< 0.001). Overall about 90% of elderly diabetic patients are 
treated with drugs for cardiovascular prevention. The largest increase during the study 
period occurred in subjects aged 65-74 years (54.8%-62.1% 2010-2014; p< 0.001). On the 
other hand the trend was downward both in the 75-84 and in ≥ 85 age groups (37.3%-
32.9% 2010-2014; 7.8%-5.0% 2010-2014 respectively). The per/patient/yearly drug costs 
was 2,349€ : 28.5% for AD therapy and 71.5% for other treatments. ConClusions: 
The results confirm the negative trends observed in other population in the use of 
AD drugs among elderly diabetic patients. Specific trend in drug utilization patterns 
showed an increased attention towards treatment recommendations in older adults. 
Safety concerns in the elderly regarding polypharmacy such as presence of multi-
morbidity and hypoglycemic episodes could also have contributed to such a trend.
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objeCtives: Diabetes mellitus type 2 (T2DM) is associated with an elevated risk of 
microvascular and macrovascular complications that are the leading cause of morbid-
ity and mortality in this patient population. In 2008, the Food and Drug Administration 
(FDA) has provided guidance for industry on how to demonstrate that new antidia-
betic drugs for T2DM are not associated with an unacceptable increase in cardiovas-
cular risk. Since introduction of the AMNOG in Germany in the year 2011, the Federal 
Joint Committee has consistently demanded the analysis of cardiovascular outcomes 
for new antidiabetics. The objective of this study is to analyze the cardiovascular risk 
associated with antidiabetics by a literature search. Methods: To identify long-term 
outcomes studies, a targeted literature research was conducted in PubMed in 2015, 
using the search terms Diabetes Mellitus, Type 2/ drug therapy/ epidemiology/ cardio-
vascular. Included studies were categorized regarding study design, patient-inclusion 
criteria, pre-existing illness, treatment duration, treatment modus and cardiovascular 
outcomes. PubMed research was supplemented by additional searches in guidelines 
in German/English language. Results: 15 outcome studies were identified in T2DM: 
UKPDS, PROactive, STOP/NIDDM, ACCORD, ADVANCE, VADT, SAVOR-TIMI, EXAMINE, 
NAVIGATOR, RECORD, Look AHEAD, ORIGIN. Studies TECOS (sitagliptin) and ELIXA 
(lixisenatide) have reported results until mid of 2015 while data from EMPA-REG 
OUTCOMETM(empagliflozin) are expected in the second half of 2015. Combined or 
single cardiovascular outcomes were used as primary endpoints by 12 studies. None 
of the outcome studies in T2DM with cardiovascular condition that have reported 
results so far could demonstrate a significant risk reduction for macrovascular events 
in the primary endpoint. ConClusions: Cardiovascular outcome studies of new 
antidiabetics are important to analyse safety of therapies as well as long-term condi-
tions and unmet need in T2DM. Especially the results of the ongoing studies are bound 
to fill the gap stressed by marketing-authorization and reimbursement agencies.
PDB17
FACtors AssoCiAteD with t2Dm treAtment ChoiCe ACross euroPe
Overbeek JA1, Heintjes EM1, Hall GC2, Lapi F3, Prieto Alhambra D4, Bezemer ID1
1PHARMo Institute for Drug outcomes Research, Utrecht, The Netherlands, 2Grimsdyke House, 
London, UK, 3Health Search, Italian College of General Practitioners and Primary Care., Firenze, 
Italy, 4IDIAP Jordi Gol, Barcelona, Spain
objeCtives: To explore demographic and clinical factors associated with choice 
of type 2 diabetes mellitus (T2DM) treatment at time of treatment intensifica-
tions. Methods: For T2DM patients from the Netherlands (NL), Italy (IT), Spain 
(ES) (2007-2011) and United Kingdom (UK) (2008-2012) antidiabetic drug prescription 
records were obtained from electronic health-care record databases. Oral mono-
therapy was defined as first-line, oral dual therapy as second-line, > 2 oral treat-
ments or oral combined with an injectable as third-line and injectables only as 
fourth-line treatment. Treatment intensification was defined as starting a higher 
line of treatment. General characteristics, comedication, comorbidities and clinical 
parameters associated with choice of treatment were identified using multivariate 
logistic regression. Results: From NL, IT, ES and UK 48,479, 67,751, 348,572 and 
152,544 T2DM patients were included, respectively. For first-line treatment advanced 
age and renal comorbidity were associated with SU (all countries), whereas high 
BMI was inversely associated in UK and ES. For second-line treatment advanced age 
was associated with biguanide + SU (all countries) and renal comorbidity with SU + 
dipeptidyl peptidase-4 inhibitors (DPP4) in UK and NL. High BMI was associated with 
biguanide + thiazolidinedione (TZD) in UK and ES, and with biguanide + DPP4 (UK 
only). For third-line treatment advanced age and renal comorbidity were associated 
with SU + insulin in ES and UK, but high BMI was inversely associated with any 
third-line treatment containing insulin. For fourth-line treatment women were more 
likely to receive glucagon-like peptide-1 analogs than men in UK and ES. Calendar 
year and prior treatment played differing roles in treatment choices in different 
countries. ConClusions: Age, BMI and renal comorbidity were the predominant 
factors associated with T2DM treatment choice across treatment intensifications 
in four EU countries. Associations identified in this explorative study are intended 
to identify questions for further research.
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